Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457332 | 0.88 | NPSR1 (0.36) | TSHRALDH1A1MAPTMAPK1ATM | |
| SCHEMBL29457333 | 0.88 | NPSR1 (0.36) | TSHRALDH1A1MAPTMAPK1ATM | |
| SCHEMBL19987096 | 0.88 | NPSR1 (0.36) | TSHRALDH1A1MAPTMAPK1ATM | |
| SCHEMBL21174043 | 0.87 | KEAP1 (0.50) | KEAP1NFE2L2 | |
| SCHEMBL5781037 | 0.87 | KEAP1 (0.50) | KEAP1NFE2L2 | |
| SCHEMBL5781044 | 0.87 | KEAP1 (0.50) | KEAP1NFE2L2 | |
| SCHEMBL21174020 | 0.81 | SLC6A12 (0.33) | TSHRALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL9077784 | 0.78 | — | — | |
| SCHEMBL9077781 | 0.78 | — | — | |
| SCHEMBL3699489 | 0.78 | TSHR (0.31) | TSHRMAPTMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115554294-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115477649-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115429798-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-109689656-B | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-10-04 | — | — | CN | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| EP-3512849-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2019-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | KEAP1 2187/4885NFE2L2 571/4885TSHR 1649/4885 |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | KEAP1 2187/4885NFE2L2 571/4885TSHR 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.